ArticleCancer immunology, immunotherapy : CII2024

The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.

Xiaoyan Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.